Float Short %

14.51

Margin Of Safety %

Put/Call OI Ratio

2.05

EPS Next Q Diff

-0.05

EPS Last/This Y

-1.13

EPS This/Next Y

-0.8

Price

Target Price

54.54

Analyst Recom

1.53

Performance Q

-10.01

Upside

-290.9%

Beta

1.22

Ticker: CLDX

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	CLDX	26.08	0.58	999.99	1862
2026-01-26	CLDX	26.58	0.58	2.67	1863
2026-01-27	CLDX	26.2	0.58	0.33	1881
2026-01-28	CLDX	24.77	0.58	0.02	1885
2026-01-29	CLDX	24.69	0.53	198.67	2002
2026-01-30	CLDX	24.64	0.92	23.52	2516
2026-02-02	CLDX	24.67	1.26	596.20	3010
2026-02-03	CLDX	25.19	3.29	128.67	5706
2026-02-05	CLDX	22.59	3.58	685.50	6100
2026-02-09	CLDX	24.65	2.75	0.04	5032
2026-02-10	CLDX	24.65	2.65	0.04	5083
2026-02-11	CLDX	24.58	2.50	0.08	5177
2026-02-12	CLDX	23.54	2.50	0.08	5177
2026-02-13	CLDX	22.97	2.43	315.90	5216
2026-02-17	CLDX	22.89	2.01	0.00	4598
2026-02-18	CLDX	23.01	1.99	999.99	4616
2026-02-19	CLDX	23.53	1.99	1.90	4617
2026-02-20	CLDX	23.02	2.05	0.02	4658
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	CLDX	25.89	-40.3	-37.7	-3.58
2026-01-26	CLDX	26.59	-40.3	-66.5	-3.58
2026-01-27	CLDX	26.20	-40.3	-48.0	-3.58
2026-01-28	CLDX	24.80	-40.3	-28.9	-3.58
2026-01-29	CLDX	24.69	-40.3	-52.7	-3.58
2026-01-30	CLDX	24.62	-40.3	-53.1	-3.58
2026-02-02	CLDX	24.67	-40.3	-56.2	-3.58
2026-02-03	CLDX	25.16	-40.3	-64.1	-3.58
2026-02-04	CLDX	24.27	-40.3	-36.8	-3.58
2026-02-05	CLDX	22.57	-40.3	-20.7	-3.58
2026-02-06	CLDX	23.78	-40.3	-80.4	-3.58
2026-02-09	CLDX	24.81	-40.3	-75.2	-3.58
2026-02-10	CLDX	24.66	-40.3	-51.5	-3.58
2026-02-11	CLDX	24.61	-40.3	-54.0	-3.58
2026-02-12	CLDX	23.54	-40.3	-33.7	-3.58
2026-02-13	CLDX	22.90	-40.3	-40.5	-3.58
2026-02-17	CLDX	22.90	-40.3	-52.3	-3.58
2026-02-18	CLDX	23.00	-40.3	-55.8	-3.58
2026-02-19	CLDX	23.53	-40.3	-	-3.58
2026-02-20	CLDX	23.00	-40.3	-	-3.58
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	CLDX	-2.77	-3.28	12.77
2026-01-26	CLDX	-2.77	-3.29	12.77
2026-01-27	CLDX	-2.77	-3.29	12.77
2026-01-28	CLDX	-2.77	-3.29	14.00
2026-01-29	CLDX	-2.77	-3.29	14.00
2026-01-30	CLDX	-2.77	-3.29	14.00
2026-02-02	CLDX	-2.77	-3.33	14.00
2026-02-03	CLDX	-2.77	-3.33	14.00
2026-02-04	CLDX	-2.77	-3.33	14.00
2026-02-05	CLDX	-2.77	-3.33	14.00
2026-02-06	CLDX	-2.77	-3.33	14.00
2026-02-09	CLDX	-2.77	-2.80	14.00
2026-02-10	CLDX	-2.77	-2.80	14.00
2026-02-11	CLDX	-2.77	-2.80	14.31
2026-02-12	CLDX	-2.77	-2.80	14.31
2026-02-13	CLDX	-2.77	-2.80	14.31
2026-02-17	CLDX	-2.74	0.03	14.31
2026-02-18	CLDX	-2.74	0.03	14.31
2026-02-19	CLDX	-2.74	0.03	14.31
2026-02-20	CLDX	-2.74	0.03	14.51
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-1.01

Avg. EPS Est. Current Quarter

-0.99

Avg. EPS Est. Next Quarter

-1.06

Insider Transactions

-2.74

Institutional Transactions

0.03

Beta

1.22

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

59.8

Max Drawdown 5-Year %

-73.1

Target Price

54.54

P/E

Forward P/E

PEG

P/S

588.33

P/B

2.56

P/Free Cash Flow

EPS

-3.38

Average EPS Est. Cur. Y

-3.58

EPS Next Y. (Est.)

-4.37

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-8635.85

Relative Volume

0.62

Return on Equity vs Sector %

-66.5

Return on Equity vs Industry %

-49.1

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Celldex Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 186

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.

stock quote shares CLDX – Celldex Therapeutics, Inc. Stock Price stock today

news today CLDX – Celldex Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch CLDX – Celldex Therapeutics, Inc. yahoo finance google finance

stock history CLDX – Celldex Therapeutics, Inc. invest stock market

stock prices CLDX premarket after hours

ticker CLDX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: CLDX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y